Halozyme Therapeutics to present its product development pipeline

NewsGuard 100/100 Score
Sep 15 2009

Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City. Jonathan Lim, M.D., President and CEO, is scheduled to present an overview of Halozyme and its product development pipeline on Tuesday, September 22, 2009 at 3:00 p.m. EDT (12:00 p.m. PDT).

To listen to the audio webcast of the presentation live or after the event, please visit the company’s Web site. The replay will be available for 30 days after the presentation.

http://www.halozyme.com/

Posted in: Pharmaceutical News

Tags: , , , , , ,

Comments (0)

Suggested Reading

Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke
New peptide library paves the way for targeting elusive cancer factor MYC
Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation
Natural killer cells lead the charge in cancer treatment innovation
Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues
Promising candidate medication for preventing and reversing fentanyl-induced overdose

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial